JPRN-UMIN000005812已完成未知
Efficacy and safety of statins for patients with chronic kidney disease - Kidney protection of statins
ihon University School of Medicine, Nephrology, Hypertension and Endocrinology0 个研究点目标入组 100 人开始时间: 2011年6月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients treated with dialysis therapy LDL cholesterol < 120 mg/d
研究者
相似试验
招募中
3 期
Investigating the therapeutic effect of statin relative to the N-acetyl cysteine in the treatment of Helicobacter pylori patientsHelicobacter pylori patients.IRCT20231017059756N1Mashhad University of Medical Sciences180
已完成
不适用
Evaluation of combination therapy with Statin and Ezetimible for patients with type II diabetes.Pateients with type II diabetes combined with dyslipidemiaJPRN-UMIN000002261Department of Cardiovascular Medicine, Saga University30
尚未招募
4 期
Efficacy of standard triple therapy with statin compared with standard triple therapy in Helicobacter pylori eradication: A randomized double- blind placebo-controlled trialTreatment in patients with Helicobacter pylori infectionStandard triple regimens, Statin, Helicobacter pylori, H.pylori, EradicationTCTR20220201001The Gastroenterological Association of Thailand (GAT)234
进行中（未招募）
1 期
Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.MedDRA version: 19.0Level: LLTClassification code 10028577Term: Myeloproliferative disorder NOSSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10028576Term: Myeloproliferative disorderSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10028538Term: Myelofibrosis with myelometaplasiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10015495Term: Essential thrombocytosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10015494Term: Essential thrombocythemiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10013238Term: Disorder myeloproliferativeSystem Organ Class: 100000004864EUCTR2016-001406-42-DKHæmatologisk Afdeling, Sjælland Sygehus, Roskilde100
终止
不适用
ow- and moderate-intensity Statin and Clinical Outcome of Primary prevention in individuals aged >75 years: the SCOPE-75 RCT StudyKCT0003629Yonsei University Health System, Severance Hospital2,484